Rodin Therapeutics was a biotechnology company focused on discovering and developing first-in-class small molecule therapeutics that modulate epigenetic mechanisms to restore synaptic function in neurodegenerative and cognitive disorders. Its research centered on selective inhibition of histone deacetylase (HDAC) complexes to strengthen neuronal connections and address synaptic dysfunction, a key feature of diseases like Alzheimer’s. The company was acquired by Alkermes in 2019, expanding its neuroscience platform and accelerating development of its CNS-focused drug candidates.